Circio Holding ASA is a clinical stage company developing immune activators to target difficult-to-treat diseases. The company’s mission is to deploy vector-based technology to create a novel class of targeted, multi-functional circRNA medicines. It has established a cutting-edge circular RNA (circRNA) program and is collaborating with Prof Michael Uhlin and a team at the Karolinska Institutet in Stockholm with the intent to develop next generation RNA therapeutics for various applications. The company also has a mutant RAS cancer vaccine program, with two collaborative clinical trials underway in the USA and Norway. It is currently looking at options for the financing of a phase 2 study for ONCOS-102, a genetically modified oncolytic adenovirus.